10-Q: Adverum Biotechnologies to Merge with Lilly, Reports Q3 Losses

Adverum Biotechnologies announced a definitive merger agreement with Eli Lilly and Company, alongside reporting significant Q3 operating losses and ongoing clinical trial progress for its lead gene therapy candidate, Ixo-vec.

Summary

• Adverum Biotechnologies has entered into a definitive merger agreement with Eli Lilly and Company, where Lilly will acquire Adverum for $3.56 per share in cash plus one non-tradable Contingent Value Right (CVR).
• The CVR offers potential payments of up to $8.91 per CVR, contingent on the U.S. approval of Ixo-vec and its achievement of $1.0 billion in annual worldwide net sales.
• The company reported a net loss of $143.9 million for the nine months ended September 30, 2025, significantly higher than the $90.0 million loss for the same period in 2024.
• Cash, cash equivalents, and short-term investments decreased to $26.1 million as of September 30, 2025, from $125.7 million at December 31, 2024.
• Research and development expenses increased by $51.8 million to $104.8 million for the nine months ended September 30, 2025, primarily due to Phase 3 clinical development activities for Ixo-vec.
• Adverum used $109.7 million in cash for operations during the nine months ended September 30, 2025, compared to $64.2 million in the prior year period.
• A Secured Promissory Note with Lilly provides up to $65.0 million in debt financing, with $20.0 million already funded and additional amounts available, expected to fund operations through the merger's consummation.
• The company settled a lawsuit related to its North Carolina premises, receiving a $9.5 million cash payment from Jaguar Gene Therapy, LLC and Advanced Medicine Partners, LLC.
• A Fourth Amendment to the North Carolina lease agreement abates rent through February 28, 2026, and includes a contingent early termination fee of a $7.4 million promissory note and $0.1 million cash.
• Substantial doubt exists regarding the company's ability to continue as a going concern, with existing cash insufficient to fund operations for at least twelve months from the filing date without the merger or additional financing.
• The ARTEMIS Phase 3 clinical trial for Ixo-vec in wet AMD completed screening on September 30, 2025, with full enrollment of at least 284 patients expected in Q4 2025 and top-line data in Q1 2027.
• The AQUARIUS Phase 3 trial for Ixo-vec is intended to be initiated in the fourth quarter of 2025.

Sentiment

Score: 4

Explanation: The company's standalone financial position is very weak, marked by significant losses, high cash burn, and a going concern warning. However, the announced merger with Eli Lilly provides a potential exit for shareholders at a fixed cash price plus contingent upside, which significantly mitigates the immediate financial distress and offers a lifeline. The sentiment is cautiously negative due to the underlying operational challenges but uplifted by the acquisition.

Positives

• The definitive merger agreement with Eli Lilly and Company provides a clear acquisition path for Adverum, offering shareholders a cash payment and potential CVR upside.
• The Contingent Value Right (CVR) offers shareholders potential additional payments of up to $8.91 per CVR upon Ixo-vec's U.S. approval and achievement of $1.0 billion in annual worldwide net sales.
• The Secured Promissory Note from Lilly provides up to $65.0 million in debt financing, addressing immediate liquidity concerns and supporting operations through the anticipated merger closing.
• Positive 52-week top-line results from the LUNA Phase 2 trial for Ixo-vec demonstrated maintenance of visual and anatomic outcomes, significant reductions in anti-VEGF injections (88% for 6E10 dose, 92% for 2E11 dose), and high injection-free rates (54% for 6E10, 69% for 2E11).
• Ixo-vec has received multiple favorable regulatory designations, including FDA Fast Track, EMA PRIME, MHRA Innovation Passport, and FDA Regenerative Medicine Advanced Therapy (RMAT) designation, which may expedite development and review.
• The settlement agreement for the North Carolina premises dispute resulted in a $9.5 million cash payment to Adverum, resolving a significant legal and financial liability.
• The Fourth Amendment to the North Carolina lease abates rent obligations through February 28, 2026, providing short-term cost relief.

Negatives

• The company incurred a substantial net loss of $143.9 million for the nine months ended September 30, 2025, an increase from $90.0 million in the prior year period.
• Cash, cash equivalents, and short-term investments significantly decreased to $26.1 million as of September 30, 2025, from $125.7 million at December 31, 2024.
• Cash used in operating activities increased substantially to $109.7 million for the nine months ended September 30, 2025, compared to $64.2 million in the same period of 2024, indicating a higher burn rate.
• The company has an accumulated deficit of $1.2 billion as of September 30, 2025, and has never achieved profitability.
• There is substantial doubt regarding the company's ability to continue as a going concern, with existing cash insufficient to fund operations for at least twelve months without the merger or additional financing.
• The merger is subject to various conditions, and there is no assurance it will be completed on time or at all, which would have a severe adverse effect on the business.
• If the merger is terminated under specified circumstances, Adverum would be required to pay Lilly a termination fee of $4.0 million.
• The CVRs are non-tradable and contingent on future milestones, meaning shareholders may not receive any payment, and the CVRs could expire valueless.
• The Secured Promissory Note from Lilly has a high interest rate (SOFR + 10.0%) and a short maturity date (January 22, 2026), with Lilly having a first-priority lien on substantially all of Adverum's assets.
• A material weakness in internal control over financial reporting related to lease accounting was identified as of December 31, 2024, and remediation is ongoing, indicating potential financial reporting risks.

Risks

• The pending merger with Eli Lilly and Company is subject to conditions beyond Adverum's control and may not be completed, potentially leading to winding down operations or bankruptcy.
• The pendency of the merger could adversely affect business, financial results, and ability to attract/retain employees or maintain relationships with partners.
• Restrictions on business activities are in place while the Merger Agreement is effective, and the Secured Promissory Note contains additional operational restrictions, with a default potentially leading to acceleration of the principal amount and bankruptcy.
• Stockholders may not receive any payment on the contingent value right (CVR), and the CVR may expire valueless.
• Substantial indebtedness has been incurred, which may decrease business flexibility, access to capital, and/or increase borrowing costs.
• There is substantial doubt regarding the company's ability to continue as a going concern, requiring significant additional funding that may not be available on acceptable terms.
• Future financings through common stock or convertible securities could result in immediate dilution for existing stockholders and a decline in stock price.
• The report of the independent registered public accounting firm for 2024 contains an explanatory paragraph regarding substantial doubt about the ability to continue as a going concern.
• Significant operating losses have been incurred since inception, and significant losses are expected for the foreseeable future, with no guarantee of achieving or sustaining profitability.
• Risks associated with subletting leased premises, including subtenant defaults, have occurred in the past and could recur.
• Business depends substantially on the success of Ixo-vec; failure to develop, obtain regulatory approval, or commercialize it would materially harm the business.
• Drug development is a long, expensive, and uncertain process, with potential for delay or failure at any stage, including serious complications or side effects.
• Results of nonclinical studies and early clinical trials are not always predictive of future results, and later trials may not be favorable or receive regulatory approval.
• Inability to successfully develop and maintain robust manufacturing processes for product candidates could delay or terminate programs.
• Changes in manufacturing methods or formulation may result in additional costs or delays.
• Inability to produce sufficient quantities of products at acceptable costs could lead to unmet demand, delayed timelines, lost revenue, reduced margins, or program termination.
• Reliance on a limited number of single-source vendors for manufacturing and testing, who may not meet regulatory requirements or have limited capacity.
• Exposure to many manufacturing and distribution risks that could increase costs and limit supply.
• Reliance on third parties for research and development, including clinical trials, who may not perform satisfactorily or meet deadlines.
• Inability to protect intellectual property and proprietary technologies, or claims by third parties of infringement, could result in liability or delay development.
• Failure to obtain or maintain necessary rights to product candidates through acquisitions and in-licenses.
• Patent protection and prosecution for some product candidates are dependent on third parties.
• Claims challenging the inventorship or ownership of patents and other intellectual property.
• Third-party patent rights could delay or adversely affect development and sale of product candidates.
• Inability to obtain intellectual property rights or protect them globally.
• Suspension or delays in clinical trials could increase costs, delay revenue generation, and adversely affect commercial prospects.
• Final marketing approval for product candidates may be delayed, limited, or denied.
• Even with regulatory approval, successful commercialization may not occur, and revenue from product sales could be limited.
• Competitors developing safer, more effective, or easier-to-administer treatments could reduce or eliminate commercial opportunity.
• Approved product candidates could be subject to restrictions or withdrawal, and non-compliance with regulatory requirements could lead to penalties.
• Coverage and reimbursement may be limited or unavailable, making profitable sales difficult.
• Healthcare and other reform legislation may increase difficulty and cost of obtaining marketing approval and commercialization, affecting prices.
• Negative public opinion and increased regulatory scrutiny of gene therapy may damage public perception or affect business/approvals.
• Dependence on key executives and scientific staff; inability to retain or recruit personnel would harm the business.
• Compromised information technology systems or data could lead to adverse consequences, including regulatory actions, litigation, and business disruption.
• Highly volatile trading price of common stock, potentially leading to substantial losses for purchasers.
• Material weakness in internal control over financial reporting; failure to remedy could adversely affect investor confidence and stock value.
• Anti-takeover provisions in charter documents and Delaware law could make an acquisition more difficult.
• Quarterly operating results may fluctuate significantly.
• Exclusive forum provisions in charter documents could limit stockholders' ability to obtain a favorable judicial forum.

Future Outlook

The company expects its cash, cash equivalents, and advances under the Secured Note with Lilly to fund operations through the anticipated consummation of the merger, which is expected to close in the fourth quarter of 2025. If the merger is not completed, substantial additional financing will be required. Adverum intends to initiate the AQUARIUS Phase 3 trial for Ixo-vec in wet AMD in Q4 2025 and expects to announce top-line data from the ARTEMIS Phase 3 trial in Q1 2027. The OPTIC extension trial is intended to be extended for another 5 years, for a total of 10 years of follow up.

Management Comments

• Our Board of Directors unanimously recommend that our shareholders tender their shares in the Offer.

Industry Context

Adverum operates in the highly competitive gene therapy and biopharmaceutical markets, specifically targeting prevalent ocular diseases like wet AMD. The acquisition by Eli Lilly highlights the ongoing trend of larger pharmaceutical companies acquiring clinical-stage biotechnology firms with promising pipeline assets, particularly in specialized areas like gene therapy. The focus on Ixo-vec for wet AMD places Adverum in a market with established anti-VEGF therapies (e.g., Eylea, Lucentis, Vabysmo) and emerging gene therapy competitors, emphasizing the need for greater durability and reduced treatment burden. The regulatory designations received by Ixo-vec reflect the industry's increasing interest in and regulatory support for advanced regenerative medicine therapies.

Comparison to Industry Standards

• Ixo-vec's LUNA Phase 2 results, showing 88% and 92% reduction in annualized anti-VEGF injections and 54% and 69% injection-free rates, suggest competitive durability compared to existing standard-of-care therapies like Eylea, Lucentis, and Vabysmo, which typically require frequent injections.
• The company faces competition from other gene therapy developers in the ocular space, such as 4D Molecular Therapeutics (developing 4D-150 for wet AMD and DME), which also aims to provide long-term efficacy.
• The acquisition by Eli Lilly, a major pharmaceutical company, indicates a validation of Ixo-vec's potential, aligning with industry trends where large players seek to integrate innovative therapies into their portfolios.
• Adverum's accumulated deficit and going concern warning are common for clinical-stage biotech companies, but the magnitude of losses and cash burn is significant, underscoring the high capital requirements and risks inherent in drug development prior to commercialization.

Corporate Governance

Legal Proceedings

• Initiated a lawsuit on April 10, 2025, against Advanced Medicine Partners, LLC (AMP) and Jaguar Gene Therapy, LLC (Jaguar) in the Superior Court of Wake County, North Carolina, to enforce rights under a sublease and seek recovery of losses and damages due to defaults by the subtenant and Jaguar for the North Carolina Premises.
• Resolved third-party contractor and subcontractor lien claims against the NC Premises on July 23, 2025, after depositing $4.8 million with the court in March 2025.
• Entered into a settlement agreement with Jaguar and AMP in October 2025, where Jaguar and AMP agreed to pay a $9.5 million cash settlement, leading to the dismissal of the lawsuit on October 9, 2025.

Related Party Transactions

• Secured Promissory Note with Eli Lilly and Company (Lilly) for up to $65.0 million in debt financing, entered into on October 24, 2025, in connection with the Merger Agreement. Lilly is the acquirer in the pending merger.
• The 2024 Private Placements on February 7, 2024, included the sale of 23,000 shares to two directors of the company at $13.50 per share, on substantially the same terms as the institutional private placement.

Stakeholder Impact

• Shareholders: Will receive $3.56 per share in cash plus one non-tradable CVR, offering a fixed value and potential contingent upside, but also face the risk of the merger not closing or the CVR expiring valueless.
• Employees: May experience uncertainty about roles due to the pending merger, potentially affecting retention and motivation. Stock option repricing aims to retain key personnel.
• Customers/Patients: Potential for Ixo-vec to become a new standard of care for wet AMD, offering durable efficacy and reduced treatment burden, if approved and successfully commercialized under Lilly's ownership.
• Creditors: Lilly, as the secured creditor under the Secured Note, has a first-priority lien on substantially all of Adverum's assets and can accelerate obligations if the merger agreement is terminated or other defaults occur.
• Landlords: The North Carolina lease settlement and amendment resolve past disputes and abate future rent obligations, but also involve a contingent early termination fee.

Next Steps

• Anticipated consummation of the merger with Eli Lilly and Company in the fourth quarter of 2025.
• Full enrollment of at least 284 patients in the ARTEMIS Phase 3 clinical trial for Ixo-vec in wet AMD expected in the fourth quarter of 2025.
• Initiation of the AQUARIUS, the second Phase 3 trial of Ixo-vec in wet AMD, in the fourth quarter of 2025.
• Presentation of long-term LUNA Phase 2 clinical data in the fourth quarter of 2025.
• Expected announcement of top-line data from the ARTEMIS Phase 3 trial in the first quarter of 2027.
• Intend to extend the OPTIC extension trial for another 5 years, for a total of 10 years of follow up.

Key Dates

Recommendation

The definitive merger agreement with Eli Lilly provides a floor for the stock price at $3.56 per share in cash, plus the potential for additional value from the contingent value rights (CVRs). While the company's standalone financial position is precarious, with significant losses and a going concern warning, the acquisition by a major pharmaceutical company offers a clear exit strategy and potential upside if Ixo-vec milestones are met. Investors should hold to realize the merger consideration and CVR potential, but new 'buy' recommendations are not warranted given the fixed cash component and the contingent, non-tradable nature of the CVR, which introduces uncertainty.

Keywords

Gene therapy, Wet AMD, Ixo-vec, Eli Lilly, Merger, Acquisition, Clinical trials, Biotechnology, Ophthalmology, Financial results, SEC filing, Contingent Value Right, R&D expenses, Going concern, Promissory note, Lease settlement